Biodexa Pharmaceuticals PLC ADR BDRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
-
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
-
Interim results for the six months ended June 30, 2026
-
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
-
Result of General Meeting
-
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
Trading Information
- Previous Close Price
- $0.43
- Day Range
- $0.44–0.47
- 52-Week Range
- $0.34–44.70
- Bid/Ask
- $0.45 / $0.46
- Shares Outstanding
- 2.20M
- Market Cap
- $469,357.00
- Volume/Avg
- 631,113 / 5M
Key Statistics
- Price/Earnings (Normalized)
- 0.01
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.biodexapharma.com
Valuation
|
Metric
|
BDRX
|
|---|---|
Price/Earnings (Normalized) | 0.01 |
Price/Book Value | 0.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BDRX
Financial Strength
|
Metric
|
BDRX
|
|---|---|
Quick Ratio | 2.41 |
Current Ratio | 2.41 |
Interest Coverage | −28.35 |
Quick Ratio
BDRX
Profitability
|
Metric
|
BDRX
|
|---|---|
Return on Assets (Normalized) | −26.18% |
Return on Equity (Normalized) | −73.30% |
Return on Invested Capital (Normalized) | −36.20% |
Return on Assets
BDRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|h#&!<n | LOCK|R>#% | $127B | |||
| Moderna Inc
MRNA
| LOCK|@?%Sn%& | LOCK|>M | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|MyrH%YH | LOCK|s^>% | $81B | |||
| argenx SE ADR
ARGX
| LOCK|CRcRt$ | LOCK|@$g | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<%TN<@t | LOCK|!K | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|MV$&Y!b | LOCK|#FF#m | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ps^qx>s | LOCK|TdMRw | $27B | |||
| Incyte Corp
INCY
| LOCK|TCP$?< | LOCK|?#? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<<y>K! | LOCK|&? | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^#^?yh | LOCK|!j | $14B |
United States